Related references
Note: Only part of the references are listed.Antiretroviral Treatment of Acute HIV Infection Normalizes Levels of Cerebrospinal Fluid Markers of Central Nervous System (CNS) Inflammation: A Consequence of a Reduced CNS Reservoir?
Magnus Gisslen et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Targeted Mitochondrial COQ10 Delivery Attenuates Antiretroviral-Drug-Induced Senescence of Neural Progenitor Cells
Martina Velichkovska et al.
MOLECULAR PHARMACEUTICS (2019)
Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects
Ignacio Perez-Valero et al.
AIDS (2019)
Differential Effects of Antiretroviral Drugs on Neurons In Vitro: Roles for Oxidative Stress and Integrated Stress Response
Anna L. Stern et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2018)
HIV-2 in the United States: rare but not forgotten
Nidhi Saraiya et al.
AIDS (2018)
Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism
Michelle L. D'Antoni et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2018)
In vitro effect of antiretroviral drugs on cultured primary astrocytes: analysis of neurotoxicity and matrix metalloproteinase inhibition
Tiziana Latronico et al.
JOURNAL OF NEUROCHEMISTRY (2018)
Organellar stress intersects the astrocyte endoplasmic reticulum, mitochondria and nucleolus in HIV associated neurodegeneration
Shruthi Nooka et al.
CELL DEATH & DISEASE (2018)
What did we learn from the bictegravir switch studies?
Marianne Harris
LANCET HIV (2018)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2018 Recommendations of the International Antiviral Society-USA Panel
Michael S. Saag et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
Rebecca Zash et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
C. Hoffmann et al.
HIV MEDICINE (2017)
Age-associated physiological and pathological changes at the blood-brain barrier: A review
Franciska Erdo et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2017)
Unmasking efavirenz neurotoxicity: Time matters to the underlying mechanisms
Nadia M. Grilo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Does efavirenz replacement improve neurological function in treated HIV infection?
B. Payne et al.
HIV MEDICINE (2017)
Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection
L. Calza et al.
HIV MEDICINE (2017)
Psychiatric Symptoms in Patients Receiving Dolutegravir
Anna Fettiplace et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2017)
Tolerability of integrase inhibitors in a real-life setting
Judit Penafiel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Paul E. Sax et al.
LANCET (2017)
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Joel Gallant et al.
LANCET (2017)
In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common Antiretrovirals
Vincent T. Ciavatta et al.
NEUROCHEMICAL RESEARCH (2017)
Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy
Rebecca Zash et al.
JAMA PEDIATRICS (2017)
HIV-1-associated inflammation and antiretroviral therapy regulate astrocyte endoplasmic reticulum stress responses
Shruthi Nooka et al.
CELL DEATH DISCOVERY (2017)
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences
Alice Tseng et al.
ANNALS OF PHARMACOTHERAPY (2017)
Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen
Hamza Coban et al.
AIDS (2017)
α7-Nicotinic acetylcholine receptor inhibition by indinavir: implications for cognitive dysfunction in treated HIV disease
Sean Ekins et al.
AIDS (2017)
Mitochondrial defects arise from nucleoside/nucleotide reverse transcriptase inhibitors in neurons: Potential contribution to HIV-associated neurocognitive disorders
Kui-Ming Hung et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2017)
Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study
Ned Sacktor et al.
NEUROLOGY (2016)
HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance
Pornpun Vivithanaporn et al.
AIDS (2016)
Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial
Alejandro Arenas-Pinto et al.
CLINICAL INFECTIOUS DISEASES (2016)
Neuropsychiatric Effects of HIV Antiviral Medications
Glenn J. Treisman et al.
DRUG SAFETY (2016)
The integrated stress response
Karolina Pakos-Zebrucka et al.
EMBO REPORTS (2016)
Enfuvirtide-PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties
Shuihong Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors
T. J. Barber et al.
HIV CLINICAL TRIALS (2016)
Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care
Julia L. Marcus et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications
Catia Marzolini et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment
Deanna Saylor et al.
NATURE REVIEWS NEUROLOGY (2016)
Maraviroc reduces neuropathic pain through polarization of microglia and astroglia - Evidence from in vivo and in vitro studies
Anna Piotrowska et al.
NEUROPHARMACOLOGY (2016)
Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics
Ankit Shah et al.
NEUROTOXICITY RESEARCH (2016)
Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?
Jonathan Underwood et al.
AIDS (2015)
Central Nervous System Penetration of Antiretroviral Drugs: Pharmacokinetic, Pharmacodynamic and Pharmacogenomic Considerations
Eric H. Decloedt et al.
CLINICAL PHARMACOKINETICS (2015)
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch
J. M. Tiraboschi et al.
HIV MEDICINE (2015)
Efavirenz and the CNS: what we already know and questions that need to be answered
Nadezda Apostolova et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders
Brigid K. Jensen et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2015)
Individual assessment of CKD risk in HIV-positive patients
Rebecca Scherzer et al.
NATURE REVIEWS NEPHROLOGY (2015)
Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy
Francesca Ferretti et al.
CURRENT HIV/AIDS REPORTS (2015)
HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies
Mark R. Etherton et al.
CURRENT INFECTIOUS DISEASE REPORTS (2015)
HIV protease inhibitors: a review of molecular selectivity and toxicity
Zhengtong Lv et al.
HIV AIDS-RESEARCH AND PALLIATIVE CARE (2015)
HIV protease inhibitor exposure predicts cerebral small vessel disease
Virawudh Soontornniyomkij et al.
AIDS (2014)
Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide An Analysis of Trial Data
Katie R. Mollan et al.
ANNALS OF INTERNAL MEDICINE (2014)
ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects
Scott L. Letendre et al.
CLINICAL INFECTIOUS DISEASES (2014)
Pharmacokinetic Enhancers in HIV Therapeutics
Kajal B. Larson et al.
CLINICAL PHARMACOKINETICS (2014)
Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs
Michael S. Abers et al.
CNS DRUGS (2014)
Drug safety profile of integrase strand transfer inhibitors
Maria del Mar Gutierrez et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor-Naive Patients
L. Curtis et al.
HIV CLINICAL TRIALS (2014)
Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz
Ana Blas-Garcia et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Verbal memory declines more rapidly with age in HIV infected versus uninfected adults
Talia R. Seider et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY (2014)
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions
Ellen C. Caniglia et al.
NEUROLOGY (2014)
Long-Term Exposure of Mice to Nucleoside Analogues Disrupts Mitochondrial DNA Maintenance in Cortical Neurons
Yulin Zhang et al.
PLOS ONE (2014)
HIV and Aging: Effects on the Central Nervous System
Silvia Canizares et al.
SEMINARS IN NEUROLOGY (2014)
Neuropathogenesis of HIV-associated neurocognitive disorders: roles for immune activation, HIV blipping and viral tropism
Maria F. Chen et al.
CURRENT OPINION IN HIV AND AIDS (2014)
A Review of the Toxicity of HIV Medications
Asa M. Margolis et al.
JOURNAL OF MEDICAL TOXICOLOGY (2014)
Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection
Tricia H. Burdo et al.
AIDS (2013)
Short Communication: Aging Not Gender Is Associated with High Atazanavir Plasma Concentrations in Asian HIV-Infected Patients
Anchalee Avihingsanon et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2013)
Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected Adults
Frederick J. Lee et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment
Noeline Nakasujja et al.
NEUROLOGY (2013)
Didanosine-Associated Retinal Toxicity in Adults Infected With Human Immunodeficiency Virus
Anna Gabrielian et al.
JAMA OPHTHALMOLOGY (2013)
Cognitive dysfunction in mitochondrial disorders
J. Finsterer
ACTA NEUROLOGICA SCANDINAVICA (2012)
Chronic Kidney Disease and Cognitive Impairment: A Systematic Review and Meta-Analysis
Thorleif Etgen et al.
AMERICAN JOURNAL OF NEPHROLOGY (2012)
Central Nervous System Viral Invasion and Inflammation During Acute HIV Infection
Victor Valcour et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120
Lucia Lisi et al.
JOURNAL OF NEUROCHEMISTRY (2012)
Soluble and Cell-Associated Insulin Receptor Dysfunction Correlates with Severity of HAND in HIV-Infected Women
Yamil Gerena et al.
PLOS ONE (2012)
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort
Marlene Smurzynski et al.
AIDS (2011)
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
Bach-Yen T. Nguyen et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALIST CANDIDATES OF THE PRIX GALIEN USA, INTERNATIONAL, AND PRO BONO HUMANITARIAN AWARDS 2010 (2011)
Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research
Lucette A. Cysique et al.
BMC NEUROLOGY (2011)
Dimethyl Fumarate, an Immune Modulator and Inducer of the Antioxidant Response, Suppresses HIV Replication and Macrophage-Mediated Neurotoxicity: A Novel Candidate for HIV Neuroprotection
Stephanie A. Cross et al.
JOURNAL OF IMMUNOLOGY (2011)
Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy
Viktor Dahl et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Minocycline treatment for HIV-associated cognitive impairment Results from a randomized trial
N. Sacktor et al.
NEUROLOGY (2011)
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients
N. Ciccarelli et al.
NEUROLOGY (2011)
A Systematic Review of the Psychiatric Side-Effects of Efavirenz
Christopher A. Kenedi et al.
AIDS AND BEHAVIOR (2011)
Age-Related Changes in Plasma Concentrations of the HIV Protease Inhibitor Lopinavir
Keith W. Crawford et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy
Ana Canestri et al.
CLINICAL INFECTIOUS DISEASES (2010)
Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
Roy T. Steigbigel et al.
CLINICAL INFECTIOUS DISEASES (2010)
Host-pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: The role of CCL2 genetic variants
Carlos Alonso-Villaverde et al.
CYTOKINE (2010)
Renal toxicity associated with tenofovir use
Sonia Rodriguez-Novoa et al.
EXPERT OPINION ON DRUG SAFETY (2010)
Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy
Aylin Yilmaz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
Jeffrey L. Lennox et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection
Christopher J. Bruno et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort
K. R. Robertson et al.
NEUROLOGY (2010)
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study
R. K. Heaton et al.
NEUROLOGY (2010)
Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer
Lianhong Xu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance
Christina M. Marraa et al.
AIDS (2009)
How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials
Andrew Hill et al.
AIDS (2009)
Acute Onset Insomnia Associated with the Initiation of Raltegravir: A Report of Two Cases and Literature Review
Jacob Gray et al.
AIDS PATIENT CARE AND STDS (2009)
Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection
Raymond Yost et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults
Jeffrey M. Jacobson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Pharmacokinetics and drug metabolism in the elderly
Ulrich Klotz
DRUG METABOLISM REVIEWS (2009)
Human Immunodeficiency Virus in an Aging Population, a Complication of Success
Jason B. Kirk et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2009)
Current and Novel Inhibitors of HIV Protease
Jana Pokorna et al.
VIRUSES-BASEL (2009)
Exacerbation of depression associated with starting raltegravir: a report of four cases
Marianne Harris et al.
AIDS (2008)
A Report on the Effect of Commencing Enfuvirtide on Peripheral Neuropathy
Catherine L. Cherry et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2008)
Human Immunodeficiency Virus Protease Inhibitors and Risk for Peripheral Neuropathy
Ronald J. Ellis et al.
ANNALS OF NEUROLOGY (2008)
Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system
Scott Letendre et al.
ARCHIVES OF NEUROLOGY (2008)
Maraviroc, risks and benefits: a review of the clinical literature
Jetske M. Emmelkamp et al.
EXPERT OPINION ON DRUG SAFETY (2008)
Class-sparing regimens for initial treatment of HIV-1 infection
Sharon A. Riddler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Updated research nosology for HIV-associated neurocognitive disorders
A. Antinori et al.
NEUROLOGY (2007)
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment
G. Schifitto et al.
NEUROLOGY (2007)
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study
Giovanni Schifitto et al.
AIDS (2007)
A brief overview of mechanisms of mitochondrial toxicity from NRTIs
James J. Kohler et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2007)
Neuropsychiatric side effects of efavirenz therapy
Gabriele Arendt et al.
EXPERT OPINION ON DRUG SAFETY (2007)
Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: Protease inhibitor-mediated neurotoxicity
JA Pettersen et al.
ANNALS OF NEUROLOGY (2006)
Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen
G Moyle et al.
HIV MEDICINE (2006)
A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20)
Roberto Manfredi et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer et al.
NATURE MEDICINE (2005)
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study
TT Brown et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Integrase inhibitors to treat HIV/AIDS
Y Pommier et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Enfuvirtide - A review of its use in the management of HIV infection
V Oldfield et al.
DRUGS (2005)
Enfuvirtide: A fusion inhibitor for the treatment of HIV infection
HB Fung et al.
CLINICAL THERAPEUTICS (2004)
Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase
RJ Bienstock et al.
MITOCHONDRION (2004)
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications
AA Mangoni et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective
W Lewis et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers
MC Poirier et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2003)
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Enfuvirtide
J LaBonte et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Market analysis
P Kirkpatrick et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
HIV-1 protease: mechanism and drug discovery
A Brik et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2003)
Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients
A Rezaie-Majd et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients
C Michelet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States
EG Bing et al.
ARCHIVES OF GENERAL PSYCHIATRY (2001)
Mitochondrial toxicity and HIV therapy
AJ White
SEXUALLY TRANSMITTED INFECTIONS (2001)
Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients
XJ Zhou et al.
AIDS (2000)
Adverse effects of antiretroviral therapy
A Carr et al.
LANCET (2000)
Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
TN Kakuda
CLINICAL THERAPEUTICS (2000)
HIV protease inhibitor-related lipodystrophy syndrome
A Carr
CLINICAL INFECTIOUS DISEASES (2000)
NNRTIs- a new class of drugs for HIV
SM Drake
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
AD Monforte et al.
AIDS (2000)
Share Paper
